Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Vaccination With CpG 7909 and Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein in Patients With NY-ESO-1-expressing Tumors

NCT00819806 is registered in ClinicalTrials.gov with Hassane M. Zarour, MD as lead sponsor.

NCT NCT00819806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00819806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Vaccination With CpG 7909 and Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein in Patients With NY-ESO-1-expressing Tumors
Lead sponsor
Hassane M. Zarour, MD
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2009
Completion date
January 31, 2015
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ny-eso-1-expressing tumors